1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
RecruitingHealthy volunteers welcome
A Pilot Study Evaluating the Safety and Efficacy of a 1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
Who can join
Ages 18 to 99 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Healthy males and females, ≥ 18 years of age at time of informed consent, seeking treatment for hair loss * Subject must voluntarily sign and date an IRB approved informed consent form * Subjects with diagnosis of biopsy proven androgenetic alopecia or scarring alopecia with hair loss recorded over the past 6 months * Subjects must have a stable hair loss treatment regimen with a plateau in results for at least 3 months * Able to read, understand and voluntarily provide written informed consent * Subject is determined to be healthy, non-smoker who agrees not to make any changes to their daily hair treatment regimen during the study * Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements * Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period Exclusion Criteria: * Subject does not have the capacity to consent to the study * Subject has other types of alopecia of the scalp like alopecia areata * History of intralesional steroid injections to the scalp in the last 12 months * Pregnant women * Any medical condition that in the consideration of the investigator, would present an increased risk of a photosensitivity reaction to the subject * Any previous surgical procedure in the treatment area in the past 12 months, or major surgery in the last 6 months * Allergy or history of prior reaction to lidocaine * History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection), and/or any history of systemic chemotherapy for prior 12 months * History or current use of the following prescription medications: i. Immunosuppressive medications/biologics, 6 months prior to and during the study ii. Accutane or other systemic retinoids within the past twelve months * Smoking or vaping in the past 12 months * History of uncontrolled hyperlipidemia, diabetes mellitus, hepatitis, or bleeding disorders * History of major depressive disorders or endocrine disorders including but not limited to; hypothyroidism, Hashimoto's thyroiditis, or hyperthyroidism
About the study
Single-center, open-label, baseline-controlled, pilot study evaluating the use of a Nonablative 1470 nm laser for the treatment of androgenetic alopecia and scarring alopecia.
What is being tested
- Sciton HALO 1470nm Non-ablative laser (device)
Sponsor: Montefiore Medical Center · Participants: 10 · Started: Dec 7, 2023
Contact the study team
- Anika Jallorina, BS · Phone: 618-704-8716
Official record on ClinicalTrials.gov — NCT05460611
Locations in the U.S.
| New York | Montefiore Einstein Advanced Care, Elmsford |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.